Luminex (NASDAQ:LMNX) posted its earnings results on Monday. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.08), Briefing.com reports. Luminex had a net margin of 5.81% and a return on equity of 4.62%. The company had revenue of $81.10 million during the quarter, compared to the consensus estimate of $80.76 million. During the same quarter in the prior year, the business earned $0.20 EPS. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year.
Shares of Luminex stock opened at $25.54 on Wednesday. The firm has a market cap of $1.25 billion, a P/E ratio of 53.21, a price-to-earnings-growth ratio of 3.51 and a beta of 0.81. Luminex has a 12 month low of $18.62 and a 12 month high of $35.37.
The firm also recently declared a quarterly dividend, which was paid on Thursday, January 10th. Investors of record on Thursday, December 20th were issued a dividend of $0.06 per share. The ex-dividend date of this dividend was Wednesday, December 19th. This represents a $0.24 dividend on an annualized basis and a yield of 0.94%. Luminex’s dividend payout ratio (DPR) is currently 50.00%.
A number of research analysts have recently weighed in on the company. ValuEngine upgraded Luminex from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 29th. BidaskClub lowered Luminex from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Zacks Investment Research lowered Luminex from a “hold” rating to a “sell” rating in a report on Friday, January 18th. TheStreet lowered Luminex from a “b-” rating to a “c+” rating in a report on Friday, December 14th. Finally, Citigroup dropped their target price on Luminex from $34.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $28.40.
A number of institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC lifted its holdings in Luminex by 0.6% during the third quarter. Teachers Advisors LLC now owns 294,425 shares of the medical instruments supplier’s stock worth $8,924,000 after acquiring an additional 1,642 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Luminex by 0.7% during the third quarter. TIAA CREF Investment Management LLC now owns 264,642 shares of the medical instruments supplier’s stock worth $8,021,000 after acquiring an additional 1,793 shares during the period. Stone Ridge Asset Management LLC lifted its holdings in Luminex by 9.1% during the third quarter. Stone Ridge Asset Management LLC now owns 24,385 shares of the medical instruments supplier’s stock worth $739,000 after acquiring an additional 2,027 shares during the period. SG Americas Securities LLC lifted its holdings in Luminex by 23.0% during the fourth quarter. SG Americas Securities LLC now owns 13,087 shares of the medical instruments supplier’s stock worth $302,000 after acquiring an additional 2,449 shares during the period. Finally, Wedge Capital Management L L P NC lifted its holdings in Luminex by 18.3% during the third quarter. Wedge Capital Management L L P NC now owns 17,827 shares of the medical instruments supplier’s stock worth $540,000 after acquiring an additional 2,756 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Luminex (LMNX) Releases Earnings Results, Misses Estimates By $0.08 EPS” was first reported by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://theenterpriseleader.com/2019/02/06/luminex-lmnx-releases-earnings-results-misses-estimates-by-0-08-eps.html.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
See Also: Discover Your Risk Tolerance
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.